Palvella Therapeutics Statistics
Total Valuation
PVLA has a market cap or net worth of $232.17 million. The enterprise value is $164.28 million.
Important Dates
The last earnings date was Thursday, May 15, 2025, before market open.
Earnings Date | May 15, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
PVLA has 11.06 million shares outstanding. The number of shares has increased by 462.52% in one year.
Current Share Class | 11.06M |
Shares Outstanding | 11.06M |
Shares Change (YoY) | +462.52% |
Shares Change (QoQ) | +0.01% |
Owned by Insiders (%) | 17.94% |
Owned by Institutions (%) | 26.46% |
Float | 5.73M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 4.07 |
P/TBV Ratio | 4.08 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.84, with a Debt / Equity ratio of 0.24.
Current Ratio | 8.84 |
Quick Ratio | 8.64 |
Debt / Equity | 0.24 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -4.27 |
Financial Efficiency
Return on equity (ROE) is -89.30% and return on invested capital (ROIC) is -34.64%.
Return on Equity (ROE) | -89.30% |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | -34.64% |
Return on Capital Employed (ROCE) | -28.68% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.63M |
Employee Count | 14 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Dividends & Yields
PVLA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -462.52% |
Shareholder Yield | -462.52% |
Earnings Yield | -10.09% |
FCF Yield | n/a |
Analyst Forecast
The average price target for PVLA is $46.29, which is 120.43% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $46.29 |
Price Target Difference | 120.43% |
Analyst Consensus | Strong Buy |
Analyst Count | 7 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |